Cost of treatment analysis for lymphoprolipherative diseases in Ukraine: pilot assessment of data
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are two of the most widespread lymphoprolipherative diseases among adult population in Ukraine and other central and western European countries. Considering that pharmaceutical treatment accounts for the greatest part of medical expenses in the management of these conditions, the aim of this study was to assess the costs of pharmacotherapy in CLL and MM. The pilot analysis was conducted retrospectively on the basis of patients’ hospital cards from specialized medical establishment in Kiev. The average annual cost of pharmaceutical treatment of patients with CLL in Ukraine was 340 750 162 RUB, and for patients with MM - 89 184 759 RUB. Negative correlation was found between the age of the patients and cost of pharmaceutical treatment.